Tobradex® Ointment
Tobramycin 0.3% / Dexamethasone 0.1% · ophthalmic ointment
Antibiotic/Steroid
Approved uses
Steroid-responsive ocular inflammation with superficial bacterial infection or a risk of it
Approximately a 1/2 inch ribbon into the conjunctival sac(s) up to three or four times daily; not more than 8 g initially
Chronic anterior uveitis, and corneal injury from chemical, radiation, or thermal burns or foreign body penetration, where superficial bacterial ocular infection or a risk of it exists
Approximately a 1/2 inch ribbon into the conjunctival sac(s) up to three or four times daily; not more than 8 g initially
Contraindications
- Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and many other viral diseases of the cornea and conjunctiva.
- Mycobacterial infection of the eye.
- Fungal diseases of ocular structures.
- Hypersensitivity to a component of the medication.
Ophthalmic ointment, tobramycin 0.3% (3 mg/g) and dexamethasone 0.1% (1 mg/g), 3.5 g tube
Dexamethasone is a potent corticoid; corticoids suppress the inflammatory response to a variety of agents and probably delay or slow healing. Because corticoids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered clinically significant. Tobramycin, the antibiotic component, is included to provide action against susceptible organisms, and in vitro studies show activity against susceptible strains of the ocular pathogens listed in the label.
Warnings & Precautions
- Not for injection into the eye: This ointment is for topical ophthalmic use.
- Aminoglycoside sensitivity: Sensitivity to topically applied aminoglycosides may occur in some patients, with reactions ranging from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions; discontinue if one occurs. Cross-sensitivity to other aminoglycoside antibiotics may occur; if hypersensitivity develops, discontinue use and institute appropriate therapy.
- IOP elevation and glaucoma: Prolonged steroid use may produce glaucoma with optic nerve damage and defects in visual acuity and visual fields; monitor IOP routinely, even though it may be difficult in pediatric and uncooperative patients.
- Posterior subcapsular cataract: Prolonged steroid use may produce it.
- Delayed corneal healing: Ophthalmic ointment may retard corneal wound healing, and delayed wound healing is separately attributed to the steroid component.
- Secondary or masked infection: Prolonged use may suppress host response and increase the hazard of secondary ocular infection; in acute purulent conditions and parasitic infections of the eye, steroids may mask infection or enhance existing infection.
- Corneal or scleral perforation: Reported with topical steroids in diseases causing thinning of the cornea or sclera.
- Fungal and nonsusceptible overgrowth: Consider fungal corneal infection after long-term steroid dosing; prolonged antibiotic use may result in overgrowth of nonsusceptible organisms, including fungi, and if superinfection occurs, initiate appropriate therapy.
- Renewal examination: Examine with magnification, such as slit lamp biomicroscopy and where appropriate fluorescein staining, when multiple prescriptions are required or whenever clinical judgment dictates.
- Contact lens wear: Lenses should not be worn during treatment, and patients with signs and symptoms of bacterial ocular infection should not wear them.
Common Side Effects
- Ocular, antibiotic component: Hypersensitivity and localized ocular toxicity, including lid itching, lid swelling, and conjunctival erythema, occur in under 4% of patients, a figure the label attributes to topical ocular tobramycin 0.3% ointment rather than to the combination.
- Ocular, steroid component: Reactions include elevation of IOP with possible glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing. The label gives no incidence figures for the combination, and exact incidence figures are not available.
- Secondary infection: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term steroid application, and fungal invasion must be considered in any persistent corneal ulceration where steroid treatment has been used. Secondary bacterial infection follows suppression of host responses.
- Postmarketing reports: Reported reactions include anaphylactic reaction and erythema multiforme.
- Systemic, steroid component: Cushing's syndrome and adrenal suppression may occur after dexamethasone in excess of the labeled dosing in predisposed patients, including children and patients on CYP3A4 inhibitors.
- Systemic, aminoglycoside class: Neurotoxicity, ototoxicity, and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy. Aminoglycosides may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson's disease.
Pregnancy: Corticosteroids have been found to be teratogenic in animal studies. Ocular administration of 0.1% dexamethasone produced fetal anomalies in 15.6% and 32.3% of two groups of pregnant rabbits, and chronic dexamethasone therapy produced fetal growth retardation and increased mortality in rats; parenteral tobramycin up to 100 mg/kg/day in rats and rabbits showed no impaired fertility and no fetal harm. No adequate and well-controlled studies in pregnant women; prolonged or repeated corticoid use in pregnancy is associated with increased risk of intrauterine growth retardation. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus, and infants of mothers who received substantial corticosteroid doses should be observed for hypoadrenalism.
Lactation: Systemically administered corticosteroids appear in human milk and could suppress growth or interfere with endogenous corticosteroid production; whether topical ocular dosing produces detectable quantities in human milk is not known, and caution should be exercised in a nursing woman.
Safety and effectiveness below age 2 have not been established.